This page shows the latest elvitegravir news and features for those working in and with pharma, biotech and healthcare.
In the US, Merck has priced Delstrigo at $70 per day, at the low end of rivals such as Gilead’s Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) and ViiV’s Triumeq
The strong uptake of ViiV's drugs comes on the back of what is viewed as a superior profile for dolutegravir compared to Gilead's current integrase inhibitor elvitegravir - found in
and Gilead's Vitekta (elvitegravir) as well as simpler, single-tablet regimens, according to GlobalData. ... HIV therapies that combine multiple drugs into one tablet such as ViiV's Triumeq (dolutegravir/abacavir/lamivudine) and Gilead's Quad product
also bagged approval for four-drug Genvoya (elvitegravir, emtricitabine, cobicistat and TAF), an updated version of the company's $1.8bn Stribild brand. ... Bictegravir - an improved follow-up to elvitegravir - is currently in phase III trials in a single
Four-drug product Genvoya (elvitegravir, emtricitabine, cobicistat and TAF) was approved in its first markets last year and is positioned to replace Gilead's $1.8bn Stribild brand.
Genvoya. HIV (in combination with cobicistat, emtricitabine and elvitegravir). nucleotide reverse transcriptase inhibitor.
More from news
Approximately 4 fully matching, plus 26 partially matching documents found.
A healthcare marketing agency that shares your passion for making things better. Our clients with solve real health problems every...